BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 16690489)

  • 1. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.
    Zhao X; Huang Q; Slovak M; Weiss L
    Am J Clin Pathol; 2006 Jun; 125(6):895-904. PubMed ID: 16690489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
    Kara IO; Sahin B; Paydas S; Cetiner S
    Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of CD56 immunohistochemical studies in follow-up of plasma cell myeloma.
    Harrington AM; Hari P; Kroft SH
    Am J Clin Pathol; 2009 Jul; 132(1):60-6. PubMed ID: 19864234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
    Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
    Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
    Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
    Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease monitoring in multiple myeloma.
    Davies FE; Rawstron AC; Owen RG; Morgan GJ
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):197-222. PubMed ID: 11987924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometric DNA quantification in immunophenotyped cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood stem cell harvests and bone marrow after therapy.
    Nowak R; Oelschlägel U; Range U; Bergmann S; Bornhäuser M; Hölig C; Schuler U; Krebs U; Günther H; Kroschinsky F; Ehninger G
    Bone Marrow Transplant; 1999 May; 23(9):895-900. PubMed ID: 10338044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens.
    Athanasiou E; Kaloutsi V; Kotoula V; Hytiroglou P; Kostopoulos I; Zervas C; Kalogiannidis P; Fassas A; Christakis JI; Papadimitriou CS
    Am J Clin Pathol; 2001 Oct; 116(4):535-42. PubMed ID: 11601138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of malignant cells in multiple myeloma bone marrow with immunoglobulin VH gene probes by fluorescent in situ hybridization and flow cytometry.
    Cao J; Vescio RA; Hong CH; Kim A; Lichtenstein AK; Berenson JR
    J Clin Invest; 1995 Mar; 95(3):964-72. PubMed ID: 7883997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring residual myeloma: high-resolution serum/urine electrophoresis or marrow biopsy with immunohistochemical analysis?
    Tatsas AD; Jagasia MH; Chen H; McCurley TL
    Am J Clin Pathol; 2010 Jul; 134(1):139-44. PubMed ID: 20551278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma.
    Wei A; Westerman D; Feleppa F; Trivett M; Juneja S
    Haematologica; 2005 Aug; 90(8):1147-9. PubMed ID: 16079123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry.
    Sarasquete ME; García-Sanz R; González D; Martínez J; Mateo G; Martínez P; Ribera JM; Hernández JM; Lahuerta JJ; Orfão A; González M; San Miguel JF
    Haematologica; 2005 Oct; 90(10):1365-72. PubMed ID: 16219573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
    Kara IO; Duman BB; Afsar CU
    J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
    Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
    Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
    Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunoglobulin heavy chain gene rearrangements in the monoclonal gammopathies].
    Bosaleh A; Denninghoff V; Garcia A; Rescia C; Avagnina A; Elsner B
    Medicina (B Aires); 2005; 65(3):219-25. PubMed ID: 16042132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of assessment of plasma cells by flow cytometry and detection of cytogenomic abnormalities by fluorescence in situ hybridization in plasma cell neoplasms.
    Lu G; Zhang XX; You MJ; Chen W
    Int J Lab Hematol; 2011 Oct; 33(5):545-50. PubMed ID: 21470373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.
    Martínez-Sánchez P; Montejano L; Sarasquete ME; García-Sanz R; Fernández-Redondo E; Ayala R; Montalbán MA; Martínez R; García Laraña J; Alegre A; Hernández B; Lahuerta JJ; Martínez-López J
    Br J Haematol; 2008 Sep; 142(5):766-74. PubMed ID: 18637804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases.
    Requena L; Kutzner H; Palmedo G; Calonje E; Requena C; Pérez G; Pastor MA; Sangueza OP
    Arch Dermatol; 2003 Apr; 139(4):475-86. PubMed ID: 12707095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques.
    Hartmann L; Biggerstaff JS; Chapman DB; Scott JM; Johnson KR; Ghirardelli KM; Fritschle WK; Martinez DL; Bennington RK; de Baca ME; Wells DA; Loken MR; Zehentner BK
    Am J Clin Pathol; 2011 Nov; 136(5):712-20. PubMed ID: 22031309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.